Treatment of Obstructive Sleep Apnea with Hypothyroidism or Acromegaly
Obstructive sleep apnea is generally resistant to pharmacological management. A clinically significant exception arises when OSA occurs in a patient with an underlying endocrine disorder — specifically hypothyroidism or acromegaly.
This protocol addresses two specific scenarios: obstructive sleep apnea with hypothyroidism, and obstructive sleep apnea with acromegaly. There are no widely effective pharmacotherapies for OSA — with the important exceptions of individuals with hypothyroidism or acromegaly, where the underlying condition contributes directly to the apnea.
The strategy focuses on the root endocrine cause rather than on the apnea in isolation. When the underlying medical condition is treated, improvement in the apnea-hypopnea index (AHI) is a defined clinical target. The specific regimen and its components are detailed in the full protocol.
There are no widely effective pharmacotherapies for OSA with the important exceptions of individuals with hypothyroidism or acromegaly.
Treatment of those underlying medical conditions can improve the AHI.
View source ↗